IL289516A - Novel peptide, compositions and method for delivery of agents into cells and tissues - Google Patents
Novel peptide, compositions and method for delivery of agents into cells and tissuesInfo
- Publication number
- IL289516A IL289516A IL289516A IL28951621A IL289516A IL 289516 A IL289516 A IL 289516A IL 289516 A IL289516 A IL 289516A IL 28951621 A IL28951621 A IL 28951621A IL 289516 A IL289516 A IL 289516A
- Authority
- IL
- Israel
- Prior art keywords
- tissues
- delivery
- agents
- compositions
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962869831P | 2019-07-02 | 2019-07-02 | |
PCT/US2020/040720 WO2021034418A2 (en) | 2019-07-02 | 2020-07-02 | Novel peptide, compositions and method for delivery of agents into cells and tissues |
Publications (1)
Publication Number | Publication Date |
---|---|
IL289516A true IL289516A (en) | 2022-03-01 |
Family
ID=74659924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL289516A IL289516A (en) | 2019-07-02 | 2021-12-30 | Novel peptide, compositions and method for delivery of agents into cells and tissues |
Country Status (9)
Country | Link |
---|---|
US (2) | US11713337B2 (en) |
EP (1) | EP3994151A4 (en) |
JP (1) | JP2022538903A (en) |
KR (1) | KR20220039725A (en) |
CN (1) | CN114555625A (en) |
AU (1) | AU2020332268A1 (en) |
CA (1) | CA3144963A1 (en) |
IL (1) | IL289516A (en) |
WO (1) | WO2021034418A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019280583B2 (en) | 2018-06-06 | 2022-12-15 | Massachusetts Institute Of Technology | Circular RNA for translation in eukaryotic cells |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5211657A (en) * | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
DE19827457C1 (en) * | 1998-06-19 | 2000-03-02 | Medigene Ag | Structural protein of AAV, its production and use |
US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
JP3635462B2 (en) * | 2000-05-31 | 2005-04-06 | 国立医薬品食品衛生研究所長 | Adenovirus vector |
SE0301431D0 (en) * | 2003-05-19 | 2003-05-19 | Dermagen | Novel antimicrobial peptides |
US8076295B2 (en) * | 2007-04-17 | 2011-12-13 | Nanotope, Inc. | Peptide amphiphiles having improved solubility and methods of using same |
JP2010537632A (en) * | 2007-08-29 | 2010-12-09 | タフツ ユニバーシティー | Methods, compositions and kits for producing and using cell penetrating peptides to improve delivery of nucleic acids, proteins, drugs, and adenoviruses to tissues and cells |
KR20100061677A (en) * | 2007-09-11 | 2010-06-08 | 몬도바이오테크 래보래토리즈 아게 | Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents |
WO2011005540A1 (en) * | 2009-06-22 | 2011-01-13 | Burnham Institute For Medical Research | Methods and compositions using peptides and proteins with c-terminal elements |
US20130158103A1 (en) * | 2011-11-23 | 2013-06-20 | The Curators Of The University Of Missouri | Method of Tissue-Selective Targeted Gene Transfer |
ES2964927T3 (en) * | 2013-12-04 | 2024-04-10 | Newleaf Symbiotics Inc | Compositions for plant treatment |
US10316061B2 (en) * | 2014-10-02 | 2019-06-11 | Temple University Of The Commonwealth System Of Higher Education | Synthesis of cell penetrating peptides for drug delivery and stem cell applications |
JP6951243B2 (en) * | 2015-03-12 | 2021-10-20 | 三洋化成工業株式会社 | Method for producing protein composition and protein composition |
CA3149413A1 (en) * | 2015-04-10 | 2016-10-13 | Feldan Bio Inc. | Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same |
-
2020
- 2020-07-02 CA CA3144963A patent/CA3144963A1/en active Pending
- 2020-07-02 KR KR1020227003440A patent/KR20220039725A/en unknown
- 2020-07-02 WO PCT/US2020/040720 patent/WO2021034418A2/en active Application Filing
- 2020-07-02 AU AU2020332268A patent/AU2020332268A1/en active Pending
- 2020-07-02 EP EP20854383.5A patent/EP3994151A4/en active Pending
- 2020-07-02 JP JP2021578241A patent/JP2022538903A/en active Pending
- 2020-07-02 CN CN202080055898.6A patent/CN114555625A/en active Pending
-
2021
- 2021-12-30 US US17/646,496 patent/US11713337B2/en active Active
- 2021-12-30 IL IL289516A patent/IL289516A/en unknown
-
2023
- 2023-06-08 US US18/331,851 patent/US20230340024A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022538903A (en) | 2022-09-06 |
EP3994151A4 (en) | 2023-07-19 |
CN114555625A (en) | 2022-05-27 |
AU2020332268A1 (en) | 2022-02-24 |
US20220204562A1 (en) | 2022-06-30 |
US11713337B2 (en) | 2023-08-01 |
CA3144963A1 (en) | 2021-02-25 |
EP3994151A2 (en) | 2022-05-11 |
WO2021034418A2 (en) | 2021-02-25 |
US20230340024A1 (en) | 2023-10-26 |
KR20220039725A (en) | 2022-03-29 |
WO2021034418A3 (en) | 2021-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276464A (en) | Methods and compositions for therapeutic protein delivery | |
IL276715A (en) | Compositions and methods for membrane protein delivery | |
EP3855909A4 (en) | Synergistic pesticidal compositions for delivery of pesticidal active ingredients and methods therefor | |
EP3840730A4 (en) | Compositions for the delivery of therapeutic agents and methods of use and making thereof | |
IL289114A (en) | Platforms, compositions, and methods for therapeutics delivery | |
EP3659585A4 (en) | Composition for delivering physiologically active ingredients into blood vessel | |
IL287082A (en) | Methods and compositions for targeted protein degradation | |
MX356671B (en) | Methods of inhibition of protein fucosylation in vivo using fucose analogs. | |
GB2608279B (en) | Therapeutic cell compositions and methods for manufacture and uses thereof | |
EP4058190A4 (en) | Compositions and methods for controlled delivery and protection of therapeutic agents | |
IL288755A (en) | Compositions and methods for biological delivery vehicles | |
IL285039A (en) | Compositions and methods for stimulating natural killer cells | |
WO2018170150A3 (en) | Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins | |
IL286776A (en) | Compositions and methods for preparing t cell compositions and uses thereof | |
EP4135677A4 (en) | Sars-2 spike protein designs, compositions and methods for their use | |
IL287981A (en) | Compositions and methods for treating t cell exhaustion | |
IL290134A (en) | Methods and compositions for reducing immunogenicity by non-depletional b cell inhibitors | |
EP3937905A4 (en) | Rinse-off compositions and uses thereof for delivery of active agents | |
EP3362048A4 (en) | Composition for intraoral delivery of biologically active peptides and proteins | |
IL289516A (en) | Novel peptide, compositions and method for delivery of agents into cells and tissues | |
EP3982942A4 (en) | Drug delivery methods and compositions | |
EP4013445A4 (en) | Therapeutic protein compositions and methods | |
EP4192958A4 (en) | Compositions and methods for increasing protein expression | |
EP3829643C0 (en) | Synergistically cooperative compositions useful for soft tissue augmentation, drug delivery and related fields | |
EP3668975A4 (en) | Compositions and methods for amino acid depletion therapy |